STAT+: A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal
Caribou Biosciences said Thursday that its CRISPR-edited T-cell therapy induced complete remissions in four of five patients with advanced B-cell lymphoma — the first clinical trial data to emerge from the biotech company co-founded by Nobel Prize winner Jennifer Doudna.
The study results are preliminary but establish Caribou’s presence among a group of drugmakers leveraging genome-editing technologies to engineer different types of immune cells into off-the-shelf, cancer-killing treatments.
